醫學系外科學科

Keyphrases

1. Stereotactic Radiosurgery 100%
2. Colorectal Cancer 88%
3. Tumor 48%
4. Gastric Cancer 43%
5. Gamma Knife Radiosurgery 43%
6. Overall Survival 39%
7. Colorectal Cancer Patients 37%
8. Taiwan 33%
9. Brain Metastases 32%
10. Metastatic Colorectal Cancer (mCRC) 32%
11. Radiosurgery 30%
12. Arteriovenous Malformation 28%
13. Prognostic Factors 24%
14. Gastric Cancer Patients 24%
15. International multicenter Study 21%
16. Multivariate Analysis 21%
17. Brain Arteriovenous Malformation (bAVM) 20%
18. Microsatellite Instability-high (MSI-H) 19%
19. Taipei 18%
20. Curative Surgery 18%
21. Lymph Node Metastasis 18%
22. Carcinoembryonic Antigen 17%
23. 5-year Survival 17%
24. General Hospital 17%
25. Chemotherapy 17%
26. Overexpression 16%
27. Disease-free Survival 16%
28. Cerebral Arteriovenous Malformation 16%
29. Colon Cancer 15%
30. Hazard Ratio 15%
31. Resection 15%
32. Obliteration 14%
33. Non-small Cell Lung Cancer (NSCLC) 14%
34. Magnetic Resonance Imaging 14%
35. Confidence Interval 13%
36. Patients with Colorectal Cancer 13%
37. Independent Prognostic Factor 12%
38. Carcinoembryonic Antigen Levels 12%
39. 5-fluorouracil (5-FU) 12%
40. Curative Resection 12%
41. Risk Factors 12%
42. Poor Prognosis 12%
43. Dural Arteriovenous Fistula (dAVF) 11%
44. Clinical Significance 11%
45. Carcinoma 11%
46. Surgical Outcomes 11%
47. Vestibular Schwannoma 10%
48. Tumor Volume 10%
49. Prognostic Value 10%
50. National Cohort Study 10%
51. Clinical Papers 10%
52. Distant Metastasis 10%
53. Tumor Size 10%
54. Colorectal Cancer Cells 10%
55. Genetic Modification 10%
56. Clinical Outcomes 9%
57. Gastric Carcinoma 9%
58. Completely Resected 9%
59. Lung Adenocarcinoma 9%
60. Gastric Adenocarcinoma 9%
61. Stomach 9%
62. Metastasis 9%
63. Tumor Recurrence 9%
64. Liver Metastasis 9%
65. High Risk 9%
66. Meningioma 8%
67. Local Tumor Control 8%
68. Leucovorin 8%
69. Surgical Resection 8%
70. Prognostic Significance 8%
71. Lymphovascular Invasion 8%
72. Colon Cancer Cells 8%
73. Patient Survival 8%
74. Multi-institutional Study 8%
75. Tumor Control 7%
76. Univariate Analysis 7%
77. Progression-free Survival 7%
78. Tumor Cells 7%
79. After Surgery 7%
80. Oxaliplatin 7%
81. Survival Rate 7%
82. Digital Subtraction Angiography 7%
83. Right-sided Colon Cancer 7%
84. Odds Ratio 7%
85. Treatment Outcome 7%
86. Overall Survival Rate 7%
87. Prognostic Indicator 6%
88. Young Patients 6%
89. Polymorphism 6%
90. Transanal Total Mesorectal Excision (taTME) 6%
91. Adverse Radiation Effect 6%
92. Embolization 6%
93. Gastrectomy 6%
94. Colorectal Carcinoma 6%
95. FOLFOX 6%
96. Mortality Rate 6%
97. Intracranial Dural Arteriovenous Fistula 6%
98. Meta-analysis 6%
99. Repeat Stereotactic Radiosurgery 6%
100. Taiwanese 6%

Medicine and Dentistry

1. Neoplasm 90%
2. Stereotactic Radiosurgery 86%
3. Colorectal Carcinoma 78%
4. Abdominal Cancer 56%
5. Surgery 45%
6. Overall Survival 43%
7. Recurrent Disease 34%
8. Prognostic Factor 30%
9. Brain Metastasis 29%
10. Arteriovenous Malformation 28%
11. Diseases 27%
12. Bleeding 26%
13. Metastatic Carcinoma 25%
14. Radiosurgery 25%
15. Colon Carcinoma 22%
16. Rectum Cancer 22%
17. Gamma Knife Radiosurgery 21%
18. Survival Rate 20%
19. Cohort Analysis 20%
20. Gastrectomy 20%
21. Lymph Node Metastasis 20%
22. Cerebral Arteriovenous Malformation 19%
23. Disease Free Survival 17%
24. Carcinoembryonic Antigen 16%
25. Malignant Neoplasm 16%
26. Multivariate Analysis 15%
27. Lung Cancer 14%
28. Lymph Node 13%
29. Dural Arteriovenous Fistula 13%
30. Non Small Cell Lung Cancer 12%
31. Breast Cancer 12%
32. Chemoradiotherapy 11%
33. Hazard Ratio 11%
34. Magnetic Resonance Imaging 10%
35. Retrospective Study 10%
36. Lung Adenocarcinoma 10%
37. Meningioma 10%
38. Carcinoma 9%
39. Liver Metastasis 9%
40. Gene Mutation 9%
41. Cancer Cell 9%
42. Cancer 8%
43. Proportional Hazards Model 8%
44. Laparoscopic Surgery 8%
45. Free Tissue Graft 8%
46. Microsatellite Instability 7%
47. Stomach Carcinoma 7%
48. Embolization 7%
49. Distant Metastasis 7%
50. Radiation Therapy 7%
51. Metastasectomy 7%
52. Stomach Adenocarcinoma 7%
53. Lymphovascular Invasion 7%
54. Carcinogenesis 7%
55. Adenocarcinoma 7%
56. Vestibular Schwannoma 7%
57. Progression Free Survival 6%
58. Metastatic Colorectal Cancer 6%
59. Total Mesorectal Excision 6%
60. Primary Tumor 6%
61. Tumor Recurrence 6%
62. Retroperitoneal Lymph Node Dissection 6%
63. Tumor Progression 6%
64. Mortality Rate 6%
65. Univariate Analysis 6%
66. Pediatrics 6%
67. Apoplexy 6%
68. In Vitro 6%
69. Cavernous Sinus 6%
70. Odds Ratio 5%
71. Meta-Analysis 5%
72. Tumor Cell 5%
73. Retrospective Cohort Study 5%
74. Randomized Controlled Trial 5%
75. Epidermal Growth Factor Receptor 5%
76. Pneumonectomy 5%
77. Intracranial Tumor 5%
78. Colorectal Surgery 5%
79. Quality of Life 5%
80. Radiation Response 5%
81. Biological Marker 5%
82. Colon 5%
83. Squamous Cell Carcinoma 5%
84. Radiation Necrosis 5%
85. Fasciocutaneous Flap 5%